Table 1 Baseline characteristics of Participants by PR Interval Status (n = 597)a
|  | PR Interval ≤ 200 ms (n = 518) | PR Interval > 200 ms (n = 79) | p-value |
|---|---|---|---|
Male [n (%)] | 334 (65%) | 67 (85%) | <0.001* |
Age (years) | 65.0 ± 11.1 | 70.5 ± 9.6 | <0.001* |
Body mass index (kgm−2) | 25.2 ± 3.5 | 25.6 ± 3.2 | 0.34 |
Coronary Artery Disease [n (%)] | 276 (53%) | 52 (66%) | 0.037* |
Prior stroke [n (%)] | 105 (21%) | 26 (33%) | 0.017* |
Diabetes mellitus [n (%)] | 274 (53%) | 36 (46%) | 0.23 |
Hypertension [n (%)] | 330 (65%) | 57 (72%) | 0.20 |
Hyperlipidemia [n (%)] | 320 (64%) | 47 (60%) | 0.48 |
Current/Past smoker [n (%)] | 211 (42%) | 43 (54%) | 0.042 |
Regular Physical activity [n (%)] | 185 (37%) | 25 (12%) | 0.40 |
Resting pulse rate (/min) | 60.3 ± 21.2 | 63.7 ± 15.4 | 0.18 |
Systolic blood pressure (mmHg) | 141.1 ± 20.5 | 140.2 ± 18.6 | 0.71 |
Diastolic blood pressure (mmHg) | 79.0 ± 9.6 | 78.7 ± 9.3 | 0.83 |
LDL-cholesterol (mmol/L) | 2.7 ± 0.7 | 2.4 ± 0.70 | 0.001* |
HDL-cholesterol (mmol/L) | 1.3 ± 0.3 | 1.2 ± 0.4 | 0.14 |
Tiglycerides (mmol/L) | 1.5 ± 1.0 | 1.4 ± 0.7 | 0.37 |
Fasting glucose (mmol/L) | 6.3 ± 2.1 | 6.1 ± 1.9 | 0.32 |
HbA1c (%) | 7.0 ± 1.5 | 6.8 ± 1.2 | 0.22 |
hs-CRP (mg/L) | 3.0 ± 8.9 | 2.7 ± 5.7 | 0.80 |
Serum creatinine (μmol/L) | 86.9 ± 29.2 | 106.9 ± 59.6 | 0.005* |
Medications: | |||
 ACEI/ARB [n (%)] | 268 (54%) | 55 (70%) | 0.008* |
 Beta-blockers [n (%)] | 241 (49%) | 43 (54%) | 0.39 |
 Calcium channel blockers [n (%)] | 140 (28%) | 22 (28%) | 0.97 |
 Aspirin [n (%)] | 323 (65%) | 62 (79%) | 0.017* |
 Statin [n (%)] | 285 (57%) | 49 (62%) | 0.41 |
PR interval (ms) | 164.7 ± 19.0 | 222.6 ± 22.0 | <0.001* |
QRS duration (ms) | 94.3 ± 27.1 | 99.0 ± 17.8 | 0.14 |
Mean Carotid IMT (mm) | 0.94 ± 0.28 | 1.05 ± 0.37 | 0.010* |